New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential.

Abstract:

:New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one immediate release and four longer-acting preparations) that have recently become available for the treatment of ADHD. While the therapeutic potential of immediate-release enantiomers of methylphenidate has not yet been clinically realised, new long-acting formulations of stimulants have changed the standard of care for children, adolescents and adults with ADHD. The longer duration of action of these once-daily compounds, and the consequent expansion of the duration of daily ADHD coverage afforded by them, has introduced the realistic possibility of reducing the overall daily burden of ADHD on affected individuals. Although more expensive, these new stimulant formulations are easier for patients to use than older stimulants, more resistant to abuse and misuse, and allow for increased privacy of ADHD treatment at school or work.

journal_name

CNS Drugs

journal_title

CNS drugs

authors

Connor DF,Steingard RJ

doi

10.2165/00023210-200418140-00005

subject

Has Abstract

pub_date

2004-01-01 00:00:00

pages

1011-30

issue

14

eissn

1172-7047

issn

1179-1934

pii

18145

journal_volume

18

pub_type

杂志文章,评审
  • Pharmacoeconomic spotlight on varenicline as an aid to smoking cessation.

    abstract::Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Varenicline was an effective aid to smoking cessation and was generally well tolerated in clinical trials, although more data are needed regarding the ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11204710-000000000-00000

    authors: Keating GM,Lyseng-Williamson KA

    更新日期:2010-09-01 00:00:00

  • Pharmacological management of postherpetic neuralgia.

    abstract::Postherpetic neuralgia, which occurs most typically in older persons, is one of the most common and serious complications of herpes zoster (or shingles). It is a chronic neuropathic pain syndrome and remains one of the most difficult pain disorders to treat. Known beneficial agents include antidepressants, antiepilept...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317110-00001

    authors: Pappagallo M,Haldey EJ

    更新日期:2003-01-01 00:00:00

  • Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.

    abstract::Oral fingolimod (Gilenya™), a sphingosine 1-phosphate (S1P) receptor agonist, is the first oral agent and the first in a novel class of disease-modifying therapies (DMTs) to be approved for use in the US for the treatment of relapsing forms of multiple sclerosis (MS). In the EU, fingolimod is approved for use as a sin...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11207350-000000000-00000

    authors: Scott LJ

    更新日期:2011-08-01 00:00:00

  • Drug Repurposing in Parkinson's Disease.

    abstract::The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug develo...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0548-y

    authors: Athauda D,Foltynie T

    更新日期:2018-08-01 00:00:00

  • Biological markers of age-related memory deficits: treatment of senescent physiology.

    abstract::In humans, age-related memory impairments begin in mid-life and cognitive weakening continues with advancing age. An important aspect of defining memory decline is the distinction between dementia as a result of neurological diseases, such as Alzheimer's disease, and memory loss not specifically associated with diseas...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620020-00006

    authors: Foster TC

    更新日期:2006-01-01 00:00:00

  • The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.

    abstract::How a woman responds to sexual cues is highly dependent on a number of distinct, yet related, factors. Researchers have attempted to explain the female sexual response for decades, but no single model reigns supreme. Proper female sexual function relies on the interplay of somatic, psychosocial and neurobiological fac...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0288-1

    authors: Kingsberg SA,Clayton AH,Pfaus JG

    更新日期:2015-11-01 00:00:00

  • The risk of stroke in patients with migraine and implications for migraine management.

    abstract::Assessing the risk of stroke in persons with migraine is complicated by the intricate relationship between these two conditions. Both migraine and stroke are common and co-morbidity may, in some cases, be coincidental. Given the overlap of clinical symptoms in stroke and migraine, each condition may also mimic the oth...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519080-00004

    authors: Tietjen GE

    更新日期:2005-01-01 00:00:00

  • Treatment Strategies for Dravet Syndrome.

    abstract::Dravet syndrome (DS) is a medically refractory epilepsy that onsets in the first year of life with prolonged seizures, often triggered by fever. Over time, patients develop other seizure types (myoclonic, atypical absences, drops), intellectual disability, crouch gait and other co-morbidities (sleep problems, autonomi...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0511-y

    authors: Knupp KG,Wirrell EC

    更新日期:2018-04-01 00:00:00

  • Selection criteria for the clinical use of the newer antiepileptic drugs.

    abstract::In recent years, several new antiepileptic drugs (AEDs) have been licensed: felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin and zonisamide. These drugs have proven efficacy as add-on therapy in patients with difficult-to-treat partial epilepsy, as 20-50% of patients ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317060-00003

    authors: Deckers CL,Knoester PD,de Haan GJ,Keyser A,Renier WO,Hekster YA

    更新日期:2003-01-01 00:00:00

  • Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.

    abstract::Schizophrenia is a long-term psychiatric disorder that impacts important mental functions and requires indefinite treatment, as well as psychosocial and economic support. The introduction of chlorpromazine, the first antipsychotic, and the subsequent development of a long list of similar dopamine-blocking antipsychoti...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0588-3

    authors: Awad AG

    更新日期:2019-01-01 00:00:00

  • Hashimoto's encephalopathy : epidemiology, pathogenesis and management.

    abstract::Hashimoto's encephalopathy is a term used to describe an encephalopathy of presumed autoimmune origin characterised by high titres of antithyroid peroxidase antibodies. In a similar fashion to autoimmune thyroid disease, Hashimoto's encephalopathy is more common in women than in men. It has been reported in paediatric...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200721100-00002

    authors: Mocellin R,Walterfang M,Velakoulis D

    更新日期:2007-01-01 00:00:00

  • Cognitive effects of statin medications.

    abstract::The demonstrated benefits of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) for cardiovascular and cerebrovascular disease are well established in the medical literature, and this class of medications is among those most commonly prescribed in the USA. In 2012, the US Food and Drug Admi...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-014-0147-5

    authors: Kelley BJ,Glasser S

    更新日期:2014-05-01 00:00:00

  • Insomnia in patients with depression: some pathophysiological and treatment considerations.

    abstract::The almost ubiquitous sleep disturbances in patients with depression commonly, but not always, subside with the remission of depression. Evidence linking insomnia with the risk of relapses in recurrent depression, as well as suicide, makes optimization of the treatment of insomnia associated with depression a priority...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200923040-00004

    authors: Jindal RD

    更新日期:2009-01-01 00:00:00

  • New formulations of existing antidepressants: advantages in the management of depression.

    abstract::For nearly 50 years, antidepressant drugs have been the first-line treatment for various forms of depression. Despite their widespread use, these medications have significant shortcomings, in particular problems of patient compliance due to adverse effects. The introduction of new formulations of existing antidepressa...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418080-00003

    authors: Norman TR,Olver JS

    更新日期:2004-01-01 00:00:00

  • Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation.

    abstract:OBJECTIVE:Many authors have reported discontinuation symptoms associated with selective serotonin reuptake inhibitors (SSRIs). The aim of this study was to investigate the incidence and characteristics of the discontinuation syndrome in patients who stopped treatment with the SSRIs paroxetine and fluoxetine under the u...

    journal_title:CNS drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00023210-200216040-00006

    authors: Bogetto F,Bellino S,Revello RB,Patria L

    更新日期:2002-01-01 00:00:00

  • Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.

    abstract::Naltrexone is a μ-opioid receptor antagonist that blocks the euphoric effects of heroin and prescription opioids. In order to improve treatment adherence, a once-monthly, intramuscular, extended-release formulation of naltrexone (XR-NTX) [VIVITROL(®)] has been developed, and approved in the USA and Russia for the prev...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0110-x

    authors: Syed YY,Keating GM

    更新日期:2013-10-01 00:00:00

  • Targeting Infectious Agents as a Therapeutic Strategy in Alzheimer's Disease.

    abstract::Alzheimer's disease (AD) is the most prevalent dementia in the world. Its cause(s) are presently largely unknown. The most common explanation for AD, now, is the amyloid cascade hypothesis, which states that the cause of AD is senile plaque formation by the amyloid β peptide, and the formation of neurofibrillary tangl...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00737-1

    authors: Fülöp T,Munawara U,Larbi A,Desroches M,Rodrigues S,Catanzaro M,Guidolin A,Khalil A,Bernier F,Barron AE,Hirokawa K,Beauregard PB,Dumoulin D,Bellenger JP,Witkowski JM,Frost E

    更新日期:2020-07-01 00:00:00

  • Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations.

    abstract::Premature mortality due to cardiovascular disease in those with schizophrenia is the largest lifespan disparity in the US and is growing; adults in the US with schizophrenia die, on average, 28 years earlier than those in the general population. The rate of smoking prevalence among individuals with schizophrenia is es...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-017-0438-8

    authors: Cather C,Pachas GN,Cieslak KM,Evins AE

    更新日期:2017-06-01 00:00:00

  • Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients.

    abstract:BACKGROUND:Antidepressant-induced liver injury is a major concern and a liver monitoring scheme has been recommended by the European Medicines Agency for agomelatine. OBJECTIVE:The objective of this study was to assess the liver safety and identify the characteristics of patients who developed a significant increase i...

    journal_title:CNS drugs

    pub_type: 杂志文章,meta分析

    doi:10.1007/s40263-016-0351-6

    authors: Perlemuter G,Cacoub P,Valla D,Guyader D,Saba B,Batailler C,Moore K

    更新日期:2016-09-01 00:00:00

  • Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.

    abstract:OBJECTIVE:To assess the relationship between the sustained pain free (SPF) and adverse event (AE) rates associated with six oral serotonin 5-HT(1B/1D) receptor agonists (triptans) used for the treatment of acute migraine, employing data from a previous meta-analysis (that included almotriptan, eletriptan, naratriptan, ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-200721010-00006

    authors: Dodick DW,Sandrini G,Williams P

    更新日期:2007-01-01 00:00:00

  • Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety.

    abstract:BACKGROUND:Dravet syndrome (DS) is one of the most severe forms of drug-resistant epilepsy and available interventions fail to control seizures in most patients. Cannabidiol (CBD) is the first in a new class of antiepileptic drugs with a distinctive chemical structure and mechanism of action. OBJECTIVE:The aim of this...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00708-6

    authors: Lattanzi S,Brigo F,Trinka E,Zaccara G,Striano P,Del Giovane C,Silvestrini M

    更新日期:2020-03-01 00:00:00

  • Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.

    abstract:BACKGROUND:Walking impairment is a hallmark of multiple sclerosis (MS). It affects > 90% of individuals over time, reducing independence and negatively impacting health-related quality of life, productivity, and daily activities. Walking impairment is consistently reported as one of the most distressing impairments by ...

    journal_title:CNS drugs

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s40263-018-0586-5

    authors: Hobart J,Ziemssen T,Feys P,Linnebank M,Goodman AD,Farrell R,Hupperts R,Blight AR,Englishby V,McNeill M,Chang I,Lima G,Elkins J,ENHANCE study investigators.

    更新日期:2019-01-01 00:00:00

  • Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study.

    abstract:BACKGROUND:Earlier commencement of clozapine has been related to a better response in treatment-resistant schizophrenia. OBJECTIVES:To identify variables that predict clozapine use after a first episode of schizophrenia (FES). METHODS:Patients with FES and ≤15 days of lifetime antipsychotic treatment were followed up...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-016-0358-z

    authors: Üçok A,Çıkrıkçılı U,Ergül C,Tabak Ö,Salaj A,Karabulut S,Correll CU

    更新日期:2016-10-01 00:00:00

  • Sodium Channel Blockers in the Treatment of Epilepsy.

    abstract::Sodium channel blockers have been the mainstay of the pharmacological management of focal and generalised tonic-clonic seizures for more than 70 years. The focus of this paper will be on phenytoin, carbamazepine, lamotrigine, oxcarbazepine, rufinamide, lacosamide and eslicarbazepine acetate. All these antiepileptic dr...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-017-0441-0

    authors: Brodie MJ

    更新日期:2017-07-01 00:00:00

  • Lacosamide: a review of its use as adjunctive therapy in the management of partial-onset seizures.

    abstract::Lacosamide (Vimpat(®)) is a functionalized amino acid available orally (as a syrup or tablet) and as an intravenous infusion. It is believed to exert its antiepileptic effect by selectively enhancing the slow inactivation of voltage-gated sodium channels. Lacosamide is approved in several countries worldwide as an adj...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0123-5

    authors: Hoy SM

    更新日期:2013-12-01 00:00:00

  • Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs.

    abstract::Multiple sclerosis (MS) has a profound impact on health-related quality of life (HRQoL), a comprehensive subjective measure of the patient's health status. Assessment of HRQoL informs on the potential advantages and disadvantages of disease-modifying drugs (DMDs) beyond their effects on observer-based disability and m...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-017-0444-x

    authors: Jongen PJ

    更新日期:2017-07-01 00:00:00

  • Taming glutamate excitotoxicity: strategic pathway modulation for neuroprotection.

    abstract::Much work has been carried out in recent years showing that elevated glutamate levels in the extracellular environment of the central nervous system play a pivotal role in neurodegeneration in acute CNS injuries. With the elucidation of the mechanism governing glutamate excitotoxicity, researchers are devising therape...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0225-3

    authors: Jia M,Njapo SA,Rastogi V,Hedna VS

    更新日期:2015-02-01 00:00:00

  • Potential of Glial Cell Modulators in the Management of Substance Use Disorders.

    abstract::The pervasive and devastating nature of substance use disorders underlies the need for the continued development of novel pharmacotherapies. We now know that glia play a much greater role in neuronal processes than once believed.  The various types of glial cells (e.g., astrocytes, microglial, oligodendrocytes) partic...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00721-9

    authors: Jones JD

    更新日期:2020-07-01 00:00:00

  • Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

    abstract::Duloxetine (Cymbalta(R)) is a potent serotonin and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) in the CNS. It is indicated for the treatment of generalized anxiety disorder (GAD) as well as other indications. In patients with GAD of at least moderate severity, oral duloxetine 60-120 mg once daily was effe...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200923060-00006

    authors: Carter NJ,McCormack PL

    更新日期:2009-01-01 00:00:00

  • Antimicrobial Use in Patients with Dementia: Current Concerns and Future Recommendations.

    abstract::Infections are common in people with dementia, and antibiotic use is widespread, albeit highly variable, across healthcare settings and countries. The few studies conducted to date that consider the appropriateness of antibiotic prescribing specifically for people with dementia focus on people with advanced dementia a...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-017-0427-y

    authors: Parsons C,van der Steen JT

    更新日期:2017-06-01 00:00:00